Antiphospholipid antibodies and multiple organ failure in critically ill cancer patients

OBJECTIVES: To describe the clinical outcomes and thrombotic events in a series of critically ill cancer patients positive for antiphospholipid (aPL) antibodies. DESIGN: Retrospective case series study. SETTING: Medical-surgical oncologic intensive care unit (ICU). PATIENTS AND PARTICIPANTS: Eighteen patients with SIRS/sepsis and multiple organ failure (MOF) and positive for aPL antibodies, included over a 10-month period. INTERVENTIONS: None MEASUREMENTS AND RESULTS: aPL antibodies and coagulation parameters were measured up to 48 hours after the occurrence of acrocyanosis or arterial/venous thrombotic events. When current criteria for the diagnosis of aPL syndrome were applied, 16 patients met the criteria for "probable" and two patients had a definite diagnosis of APL syndrome in its catastrophic form (CAPS). Acrocyanosis, arterial events and venous thrombosis were present in eighteen, nine and five patients, respectively. Sepsis, cancer and major surgery were the main precipitating factors. All patients developed MOF during the ICU stay, with a hospital mortality rate of 72% (13/18). Five patients were discharged from the hospital. There were three survivors at 90 days of follow-up. New measurements of lupus anticoagulant (LAC) antibodies were performed in these three survivors and one patient still tested positive for these antibodies. CONCLUSIONS: In this small series of patients, we observed a high frequency of auto-antibodies and micro- and macro-vascular thrombotic events in critically ill cancer patients. The coexistence of sepsis or SIRS and aPL antibodies was often associated with MOF and death. More studies are necessary to determine the pathophysiological significance of antiphospholipid antibodies in severely ill cancer patients.

Saved in:
Bibliographic Details
Main Authors: Salluh,Jorge I. F., Soares,Márcio, Meis,Ernesto De
Format: Digital revista
Language:English
Published: Faculdade de Medicina / USP 2009
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322009000200003
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1807-59322009000200003
record_format ojs
spelling oai:scielo:S1807-593220090002000032009-06-18Antiphospholipid antibodies and multiple organ failure in critically ill cancer patientsSalluh,Jorge I. F.Soares,MárcioMeis,Ernesto De Antiphospholipid syndrome Multiple organ failure Cancer Thrombosis Sepsis Lupus anticoagulant OBJECTIVES: To describe the clinical outcomes and thrombotic events in a series of critically ill cancer patients positive for antiphospholipid (aPL) antibodies. DESIGN: Retrospective case series study. SETTING: Medical-surgical oncologic intensive care unit (ICU). PATIENTS AND PARTICIPANTS: Eighteen patients with SIRS/sepsis and multiple organ failure (MOF) and positive for aPL antibodies, included over a 10-month period. INTERVENTIONS: None MEASUREMENTS AND RESULTS: aPL antibodies and coagulation parameters were measured up to 48 hours after the occurrence of acrocyanosis or arterial/venous thrombotic events. When current criteria for the diagnosis of aPL syndrome were applied, 16 patients met the criteria for "probable" and two patients had a definite diagnosis of APL syndrome in its catastrophic form (CAPS). Acrocyanosis, arterial events and venous thrombosis were present in eighteen, nine and five patients, respectively. Sepsis, cancer and major surgery were the main precipitating factors. All patients developed MOF during the ICU stay, with a hospital mortality rate of 72% (13/18). Five patients were discharged from the hospital. There were three survivors at 90 days of follow-up. New measurements of lupus anticoagulant (LAC) antibodies were performed in these three survivors and one patient still tested positive for these antibodies. CONCLUSIONS: In this small series of patients, we observed a high frequency of auto-antibodies and micro- and macro-vascular thrombotic events in critically ill cancer patients. The coexistence of sepsis or SIRS and aPL antibodies was often associated with MOF and death. More studies are necessary to determine the pathophysiological significance of antiphospholipid antibodies in severely ill cancer patients.info:eu-repo/semantics/openAccessFaculdade de Medicina / USPClinics v.64 n.2 20092009-02-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322009000200003en10.1590/S1807-59322009000200003
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Salluh,Jorge I. F.
Soares,Márcio
Meis,Ernesto De
spellingShingle Salluh,Jorge I. F.
Soares,Márcio
Meis,Ernesto De
Antiphospholipid antibodies and multiple organ failure in critically ill cancer patients
author_facet Salluh,Jorge I. F.
Soares,Márcio
Meis,Ernesto De
author_sort Salluh,Jorge I. F.
title Antiphospholipid antibodies and multiple organ failure in critically ill cancer patients
title_short Antiphospholipid antibodies and multiple organ failure in critically ill cancer patients
title_full Antiphospholipid antibodies and multiple organ failure in critically ill cancer patients
title_fullStr Antiphospholipid antibodies and multiple organ failure in critically ill cancer patients
title_full_unstemmed Antiphospholipid antibodies and multiple organ failure in critically ill cancer patients
title_sort antiphospholipid antibodies and multiple organ failure in critically ill cancer patients
description OBJECTIVES: To describe the clinical outcomes and thrombotic events in a series of critically ill cancer patients positive for antiphospholipid (aPL) antibodies. DESIGN: Retrospective case series study. SETTING: Medical-surgical oncologic intensive care unit (ICU). PATIENTS AND PARTICIPANTS: Eighteen patients with SIRS/sepsis and multiple organ failure (MOF) and positive for aPL antibodies, included over a 10-month period. INTERVENTIONS: None MEASUREMENTS AND RESULTS: aPL antibodies and coagulation parameters were measured up to 48 hours after the occurrence of acrocyanosis or arterial/venous thrombotic events. When current criteria for the diagnosis of aPL syndrome were applied, 16 patients met the criteria for "probable" and two patients had a definite diagnosis of APL syndrome in its catastrophic form (CAPS). Acrocyanosis, arterial events and venous thrombosis were present in eighteen, nine and five patients, respectively. Sepsis, cancer and major surgery were the main precipitating factors. All patients developed MOF during the ICU stay, with a hospital mortality rate of 72% (13/18). Five patients were discharged from the hospital. There were three survivors at 90 days of follow-up. New measurements of lupus anticoagulant (LAC) antibodies were performed in these three survivors and one patient still tested positive for these antibodies. CONCLUSIONS: In this small series of patients, we observed a high frequency of auto-antibodies and micro- and macro-vascular thrombotic events in critically ill cancer patients. The coexistence of sepsis or SIRS and aPL antibodies was often associated with MOF and death. More studies are necessary to determine the pathophysiological significance of antiphospholipid antibodies in severely ill cancer patients.
publisher Faculdade de Medicina / USP
publishDate 2009
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322009000200003
work_keys_str_mv AT salluhjorgeif antiphospholipidantibodiesandmultipleorganfailureincriticallyillcancerpatients
AT soaresmarcio antiphospholipidantibodiesandmultipleorganfailureincriticallyillcancerpatients
AT meisernestode antiphospholipidantibodiesandmultipleorganfailureincriticallyillcancerpatients
_version_ 1756432034600845312